Citius Pharmaceuticals (NASDAQ:CTXR) Given Buy Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR) in a research report released on Tuesday,Benzinga reports. D. Boral Capital currently has a $9.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th.

Citius Pharmaceuticals Price Performance

Shares of Citius Pharmaceuticals stock opened at $2.48 on Tuesday. The business has a 50-day moving average of $3.14 and a 200-day moving average of $8.36. The company has a market capitalization of $21.26 million, a PE ratio of -0.41 and a beta of 1.28. Citius Pharmaceuticals has a 1-year low of $2.42 and a 1-year high of $26.75.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its earnings results on Friday, February 14th. The company reported ($1.30) earnings per share for the quarter, missing the consensus estimate of ($1.25) by ($0.05). On average, equities analysts expect that Citius Pharmaceuticals will post -4.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Citius Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its stake in Citius Pharmaceuticals by 14.1% in the third quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock worth $941,000 after purchasing an additional 232,656 shares in the last quarter. Chelsea Counsel Co. grew its stake in Citius Pharmaceuticals by 9.8% in the third quarter. Chelsea Counsel Co. now owns 281,300 shares of the company’s stock worth $141,000 after purchasing an additional 25,000 shares in the last quarter. Arkadios Wealth Advisors grew its stake in Citius Pharmaceuticals by 33.3% in the third quarter. Arkadios Wealth Advisors now owns 200,000 shares of the company’s stock worth $100,000 after purchasing an additional 50,000 shares in the last quarter. Virtu Financial LLC acquired a new position in Citius Pharmaceuticals in the third quarter worth about $50,000. Finally, Miller Investment Management LP boosted its stake in Citius Pharmaceuticals by 99.3% in the third quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock valued at $50,000 after acquiring an additional 49,640 shares during the period. 16.88% of the stock is currently owned by institutional investors and hedge funds.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.